Side-effect in the treatment of pulmonary tuberculosis by first-line drugs Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Experience of isofon use for therapy and chemoprophylaxis of tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 486s Year: 2004
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 53 (1) 1801154; 10.1183/13993003.01154-2018 Year: 2019
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Diaskintest at patients after successful treatment of lung tuberculosis Source: International Congress 2017 – Migrants and screening Year: 2017
On abandon of the tuberculosis treatment Source: Eur Respir J 2003; 22: Suppl. 45, 522s Year: 2003
The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Surgical treatment of first found pulmonary tuberculosis at ineffectiveness of DOTS therapy Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018 Year: 2019
The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010